{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:58:57Z","timestamp":1793897937866,"version":"4.8.0"},"reference-count":55,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T00:00:00Z","timestamp":1740700800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"U.S Department of Health and Human Services (HHS)","award":["HHSO100201700012C"],"award-info":[{"award-number":["HHSO100201700012C"]}]},{"name":"U.S Department of Health and Human Services (HHS)","award":["HDTRA1-15-C-0058"],"award-info":[{"award-number":["HDTRA1-15-C-0058"]}]},{"name":"U.S Department of Health and Human Services (HHS)","award":["CB10069"],"award-info":[{"award-number":["CB10069"]}]},{"name":"Administration for Strategic Preparedness and Response (ASPR)","award":["HHSO100201700012C"],"award-info":[{"award-number":["HHSO100201700012C"]}]},{"name":"Administration for Strategic Preparedness and Response (ASPR)","award":["HDTRA1-15-C-0058"],"award-info":[{"award-number":["HDTRA1-15-C-0058"]}]},{"name":"Administration for Strategic Preparedness and Response (ASPR)","award":["CB10069"],"award-info":[{"award-number":["CB10069"]}]},{"name":"Biomedical Advanced Research and Development Authority (BARDA)","award":["HHSO100201700012C"],"award-info":[{"award-number":["HHSO100201700012C"]}]},{"name":"Biomedical Advanced Research and Development Authority (BARDA)","award":["HDTRA1-15-C-0058"],"award-info":[{"award-number":["HDTRA1-15-C-0058"]}]},{"name":"Biomedical Advanced Research and Development Authority (BARDA)","award":["CB10069"],"award-info":[{"award-number":["CB10069"]}]},{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HHSO100201700012C"],"award-info":[{"award-number":["HHSO100201700012C"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["HDTRA1-15-C-0058"],"award-info":[{"award-number":["HDTRA1-15-C-0058"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","award":["CB10069"],"award-info":[{"award-number":["CB10069"]}],"id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA","award":["HHSO100201700012C"],"award-info":[{"award-number":["HHSO100201700012C"]}]},{"name":"Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA","award":["HDTRA1-15-C-0058"],"award-info":[{"award-number":["HDTRA1-15-C-0058"]}]},{"name":"Merck Sharp &amp; Dohme LLC, a subsidiary of Merck &amp; Co., Inc., Rahway, NJ, USA","award":["CB10069"],"award-info":[{"award-number":["CB10069"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The recombinant vesicular stomatitis virus-Zaire Ebolavirus envelope glycoprotein vaccine (rVSV\u0394G-ZEBOV-GP) was highly effective against Ebola virus disease in a ring vaccination trial conducted during the 2014\u20132016 outbreak in Guinea and is licensed by regulatory agencies including US FDA, EMA, and prequalified by WHO. Vaccination studies in a nonhuman primate (NHP) model guided initial dose selection for clinical trial evaluation. We summarize two dose-ranging studies with the clinical-grade rVSV\u0394G-ZEBOV-GP vaccine candidate to assess the impact of dose level on immune responses and efficacy in an NHP Ebola virus (EBOV) challenge model. Forty-six cynomolgus macaques were vaccinated with a wide range of rVSV\u0394G-ZEBOV-GP doses and challenged 42 days later intramuscularly with 1000 pfu EBOV. Vaccination with rVSV\u0394G-ZEBOV-GP induced relatively high levels of EBOV-specific IgG and neutralizing antibodies, measured using the same validated assays as used in rVSV\u0394G-ZEBOV-GP clinical trials. Similar responses were observed across dose groups from 1 \u00d7 108 to 1 \u00d7 102 pfu. A single vaccination conferred 98% protection from lethal intramuscular EBOV challenge across all dose groups. These results demonstrate that robust antibody titers are induced in NHPs across a wide range of rVSV\u0394G-ZEBOV-GP vaccine doses, correlating with high levels of protection against death from EBOV challenge.<\/jats:p>","DOI":"10.3390\/v17030341","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T04:28:18Z","timestamp":1740716898000},"page":"341","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["rVSV\u0394G-ZEBOV-GP Vaccine Is Highly Immunogenic and Efficacious Across a Wide Dose Range in a Nonhuman Primate EBOV Challenge Model"],"prefix":"10.3390","volume":"17","author":[{"given":"Amy C.","family":"Shurtleff","sequence":"first","affiliation":[{"name":"US Army Medical Research Institute of Infectious Diseases (USAMRIID), Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Trefry","sequence":"additional","affiliation":[{"name":"US Army Medical Research Institute of Infectious Diseases (USAMRIID), Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheri","family":"Dubey","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melek M. E.","family":"Sunay","sequence":"additional","affiliation":[{"name":"US Army Medical Research Institute of Infectious Diseases (USAMRIID), Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Liu","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Eichberg","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Silvera","sequence":"additional","affiliation":[{"name":"US Army Medical Research Institute of Infectious Diseases (USAMRIID), Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0383-3879","authenticated-orcid":false,"given":"Steve A.","family":"Kwilas","sequence":"additional","affiliation":[{"name":"US Army Medical Research Institute of Infectious Diseases (USAMRIID), Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4475-0415","authenticated-orcid":false,"given":"Jay W.","family":"Hooper","sequence":"additional","affiliation":[{"name":"US Army Medical Research Institute of Infectious Diseases (USAMRIID), Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Martin","sequence":"additional","affiliation":[{"name":"US Army Medical Research Institute of Infectious Diseases (USAMRIID), Porter Street, Fort Detrick, Frederick, MD 21702, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub K.","family":"Simon","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth-Ann G.","family":"Coller","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., 126 E. Lincoln Ave., Rahway, NJ 07065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Monath","sequence":"additional","affiliation":[{"name":"NewLink Genetics Corp., Loop Dr #5100, Ames, IA 50010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,28]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (WHO) (2024, November 08). Ebola Virus Disease, Available online: https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/ebola-virus-disease."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3201\/eid2502.181011","article-title":"Ebola Virus Infection Associated with Transmission from Survivors","volume":"25","author":"Marston","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/JVI.78.2.958-967.2004","article-title":"Persistent infection with ebola virus under conditions of partial immunity","volume":"78","author":"Gupta","year":"2004","journal-title":"J. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Thorson, A.E., Deen, G.F., Bernstein, K.T., Liu, W.J., Yamba, F., Habib, N., Sesay, F.R., Gaillard, P., Massaquoi, T.A., and McDonald, S.L.R. (2021). Persistence of Ebola virus in semen among Ebola virus disease survivors in Sierra Leone: A cohort study of frequency, duration, and risk factors. PLoS Med., 18.","DOI":"10.1371\/journal.pmed.1003273"},{"key":"ref_5","unstructured":"Centers for Disease Control and Prevention (CDC) (2024, November 08). Outbreak History, Available online: https:\/\/www.cdc.gov\/ebola\/outbreaks\/index.html."},{"key":"ref_6","unstructured":"Centers for Disease Control and Prevention (CDC) (2024, November 06). Ebola Disease Basics, Available online: https:\/\/www.cdc.gov\/ebola\/about\/index.html."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.medmal.2014.08.005","article-title":"Case fatality rates of Ebola virus diseases: A meta-analysis of World Health Organization data","volume":"44","author":"Lefebvre","year":"2014","journal-title":"Med. Mal. Infect."},{"key":"ref_8","unstructured":"U.S. Food and Drug Administration (2022, August 26). FDA Approves Treatment for Ebola Virus [Press Release], Available online: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-ebola-virus."},{"key":"ref_9","unstructured":"U.S. Food and Drug Administration (2022, August 26). FDA Approves First Treatment for Ebola Virus [Press Release], Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-ebola-virus."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100009","DOI":"10.1016\/j.jvacx.2019.100009","article-title":"rVSV\u0394G-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk\/benefit assessment","volume":"1","author":"Monath","year":"2019","journal-title":"Vaccine X"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Coller, B.G., Lapps, W., Yunus, M., Bruno, S., Eichberg, M.J., Lee, A.W., Liu, K., Drury, R., Millogo, J., and Macareo, L.R. (2022). Lessons Learned from the Development and Roll-Out of the rVSV\u0394G-ZEBOV-GP Zaire ebolavirus Vaccine to Inform Marburg Virus and Sudan ebolavirus Vaccines. Vaccines, 10.","DOI":"10.3390\/vaccines10091446"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Agnandji, S.T., Fernandes, J.F., Bache, E.B., Obiang Mba, R.M., Brosnahan, J.S., Kabwende, L., Pitzinger, P., Staarink, P., Massinga-Loembe, M., and Kr\u00e4hling, V. (2017). Safety and immunogenicity of rVSV\u0394G-ZEBOV-GP Ebola vaccine in adults and children in Lambar\u00e9n\u00e9, Gabon: A phase I randomised trial. PLoS Med., 14.","DOI":"10.1371\/journal.pmed.1002402"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ebiom.2017.03.045","article-title":"Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization","volume":"19","author":"Dahlke","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"E819","DOI":"10.1503\/cmaj.170074","article-title":"Canadian Immunization Research Network, Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: A randomized clinical trial","volume":"189","author":"ElSherif","year":"2017","journal-title":"CMAJ"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S1473-3099(17)30313-4","article-title":"Safety and immunogenicity of the rVSV\u0394G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: A phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study","volume":"17","author":"Heppner","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1414216","article-title":"rVSV\u0394G-ZEBOV-GP Study Group, A Recombinant Vesicular Stomatitis Virus Ebola Vaccine","volume":"376","author":"Regules","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1093\/infdis\/jix189","article-title":"Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults","volume":"215","author":"Halperin","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/infdis\/jiz241","article-title":"V920-012 Study Team, Immunogenicity, Lot Consistency, and Extended Safety of rVSV\u0394G-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults","volume":"220","author":"Halperin","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!)","volume":"389","author":"Camacho","year":"2017","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1056\/NEJMoa1614067","article-title":"Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia","volume":"377","author":"Kennedy","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1093\/infdis\/jiy020","article-title":"The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV\u0394G-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak","volume":"217","author":"Samai","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.cmi.2023.08.026","article-title":"Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability","volume":"29","author":"Huttner","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Prevac Study Team, Kieh, M., Richert, L., Beavogui, A.H., Grund, B., Leigh, B., D\u2019Ortenzio, E., Doumbia, S., Lhomme, E., and Sow, S. (2022). Randomized Trial of Vaccines for Zaire Ebola Virus Disease. N. Engl. J. Med., 387, 2411\u20132424.","DOI":"10.1056\/NEJMoa2200072"},{"key":"ref_27","unstructured":"(2024, November 08). European Medicines Agency Ervebo: EPAR\u2014Product Information. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ervebo."},{"key":"ref_28","unstructured":"U.S. Food and Drug Administration (2020, February 17). First FDA-Approved Vaccine for the Prevention of Ebola Virus Disease, Marking a Critical Milestone in Public Health Preparedness and Response, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health."},{"key":"ref_29","unstructured":"(2023). ERVEBO\u00ae Prescribing Information, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"360","DOI":"10.15585\/mmwr.mm7316a1","article-title":"Use of Ebola Vaccines\u2014Worldwide, 2021\u20132023","volume":"73","author":"Kallay","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_31","unstructured":"European Medicines Agency (2024, October 22). New Vaccine for Prevention of Ebola Virus Disease Recommended for Approval in the European Union, Available online: https:\/\/www.ema.europa.eu\/en\/news\/new-vaccine-prevention-ebola-virus-disease-recommended-approval-european-union."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Geisbert, T.W., Daddario-DiCaprio, K.M., Lewis, M.G., Geisbert, J.B., Grolla, A., Leung, A., Paragas, J., Matthias, L., Smith, M.A., and Jones, S.M. (2008). Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLoS Pathog., 4.","DOI":"10.1371\/journal.ppat.1000225"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.1128\/JVI.00561-09","article-title":"Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus","volume":"83","author":"Geisbert","year":"2009","journal-title":"J. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Qiu, X., Fernando, L., Alimonti, J.B., Melito, P.L., Feldmann, F., Dick, D., Stroher, U., Feldmann, H., and Jones, S.M. (2009). Mucosal immunization of cynomolgus macaques with the VSV\u0394G\/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005547"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Kugelman, J.R., Rossi, C.A., Wiley, M.R., Ladner, J.T., Nagle, E.R., Pfeffer, B.P., Garcia, K., Prieto, K., Wada, J., and Kuhn, J.H. (2016). Informing the Historical Record of Experimental Nonhuman Primate Infections with Ebola Virus: Genomic Characterization of USAMRIID Ebola Virus\/H.sapiens-tc\/COD\/1995\/Kikwit-9510621 Challenge Stock \u201cR4368\u201d and Its Replacement \u201cR4415\u201d. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0150919"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6739","DOI":"10.3390\/v7122969","article-title":"Ebola Virus Infections in Nonhuman Primates Are Temporally Influenced by Glycoprotein Poly-U Editing Site Populations in the Exposure Material","volume":"7","author":"Trefry","year":"2015","journal-title":"Viruses"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1093\/infdis\/jiv284","article-title":"Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection","volume":"212","author":"Geisbert","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Shurtleff, A.C., Bloomfield, H.A., Mort, S., Orr, S.A., Audet, B., Whitaker, T., Richards, M.J., and Bavari, S. (2016). Validation of the Filovirus Plaque Assay for Use in Preclinical Studies. Viruses, 8.","DOI":"10.3390\/v8040113"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Rudge, T.L., Sankovich, K.A., Niemuth, N.A., Anderson, M.S., Badorrek, C.S., Skomrock, N.D., Cirimotich, C.M., and Sabourin, C.L. (2019). Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0215457"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Niemuth, N.A., Rudge, T.L., Sankovich, K.A., Anderson, M.S., Skomrock, N.D., Badorrek, C.S., and Sabourin, C.L. (2020). Method feasibility for cross-species testing, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for non-human primate serum samples. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0241016"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1016\/S2666-5247(20)30198-1","article-title":"Estimation of the correlates of protection of the rVSV\u0394G-ZEBOV-GP Zaire ebolavirus vaccine: A post-hoc analysis of data from phase 2\/3 clinical trials","volume":"2","author":"Grais","year":"2021","journal-title":"Lancet Microbe"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Warren, T., Zumbrun, E., Weidner, J.M., Gomba, L., Rossi, F., Bannister, R., Tarrant, J., Reed, M., Lee, E., and Raymond, J.L. (2020). Characterization of Ebola Virus Disease (EVD) in Rhesus Monkeys for Development of EVD Therapeutics. Viruses, 12.","DOI":"10.3390\/v12010092"},{"key":"ref_45","unstructured":"Parrott, T. (2024, June 17). Miscellaneous Conditions of Nonhuman Primates. Available online: https:\/\/www.msdvetmanual.com\/exotic-and-laboratory-animals\/nonhuman-primates\/miscellaneous-conditions-of-nonhuman-primates."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa1411680","article-title":"Clinical illness and outcomes in patients with Ebola in Sierra Leone","volume":"371","author":"Schieffelin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1473-3099(18)30165-8","article-title":"Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: An observational cohort study","volume":"18","author":"Huttner","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ebiom.2019.09.055","article-title":"Single low-dose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge","volume":"49","author":"Marzi","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"112402","DOI":"10.1016\/j.celrep.2023.112402","article-title":"Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates","volume":"42","author":"Gunn","year":"2023","journal-title":"Cell Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aab3920","article-title":"VSV-EBOV rapidly protects macaques against infection with the 2014\/15 Ebola virus outbreak strain","volume":"349","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1016\/j.vaccine.2020.04.061","article-title":"Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus\u2013Zaire Ebola virus envelope glycoprotein vaccine: An evidence-based analysis","volume":"38","author":"Antonello","year":"2020","journal-title":"Vaccine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1500306","article-title":"Persistence of Ebola Virus in Ocular Fluid during Convalescence","volume":"372","author":"Varkey","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1056\/NEJMoa1511410","article-title":"Ebola RNA Persistence in Semen of Ebola Virus Disease Survivors\u2013Final Report","volume":"377","author":"Deen","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Schindell, B.G., Webb, A.L., and Kindrachuk, J. (2018). Persistence and Sexual Transmission of Filoviruses. Viruses, 10.","DOI":"10.3390\/v10120683"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat. Rev. Dis. Primers"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/3\/341\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:44:26Z","timestamp":1760028266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/17\/3\/341"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,28]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["v17030341"],"URL":"https:\/\/doi.org\/10.3390\/v17030341","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,28]]}}}